Preservative-free 0.01% bimatoprost versus other formulations for glaucoma and OHT: Systematic review and meta-analysis of efficacy and safety
Open Access
- 1 April 2026
- journal article
- review article
- Published by SAGE Publications in European Journal of Ophthalmology
Abstract
Purpose: To demonstrate non-inferiority on efficacy and safety of preservative-free bimatoprost 0.01% versus preserved and higher-concentration bimatoprost formulations for the treatment of glaucoma or ocular hypertension (OHT), using a network meta-analysis (NMA). Methods: A systematic review and Bayesian NMA were conducted according to a pre-registered protocol (PROSPERO: CRD420250650769) and PRISMA-NMA guidelines. Randomised controlled trials comparing monotherapies of bimatoprost (preserved or preservative-free) in adults with glaucoma or OHT were included. The primary endpoint was mean intraocular pressure (IOP) at Week 12. Conjunctival hyperaemia, were descriptively analysed. Risk of bias was assessed using the Cochrane RoB 2 tool. Results: Four studies were included. The Bayesian NMA demonstrated that preservative-free bimatoprost 0.01% was non-inferior to all other bimatoprost formulations in lowering IOP, with all 95% credible intervals falling within the 1.5 mmHg non-inferiority margin. Sensitivity analyses using a frequentist model confirmed these findings. Safety analysis indicated that preservative-free bimatoprost formulations were associated with lower rates of hyperaemia compared to preserved versions. At Week 12, more patients had no hyperaemia with preservative-free bimatoprost 0.01% (57.3% vs. 43.6%) and fewer showed worsening scores (18.3% vs. 30.4%). Hyperaemia reported as an adverse event was also less frequent with bimatoprost 0.01% than 0.03% (28.6% vs. 37.4%). Conclusions: Preservative-free bimatoprost 0.01% provided IOP-lowering efficacy similar to preserved or higher-dose bimatoprost, with less occurrence of conjunctival hyperaemia. Further long-term studies are needed to confirm these benefits.Keywords
Funding Information
- Laboratoires Théa
This publication has 35 references indexed in Scilit:
- A Narrative Review of Ocular Surface Disease Related to Anti-Glaucomatous MedicationsOphthalmology and Therapy, 2022
- Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2)Drugs, 2021
- Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1)Ophthalmology, 2020
- Twelve-Month, Randomized, Controlled Trial of Bimatoprost 0.01%, 0.0125%, and 0.03% in Patients with Glaucoma or Ocular HypertensionAmerican Journal of Ophthalmology, 2010
- Adherence and Persistence with Glaucoma TherapySurvey of Ophthalmology, 2008
- Cochrane Handbook for Systematic Reviews of Interventions2008
- Quantitative analysis of conjunctival goblet cells after chronic application of topical dropsAdvances in Therapy, 2008
- Patient-Reported Behavior and Problems in Using Glaucoma MedicationsOphthalmology, 2006
- One-Year, Randomized Study Comparing Bimatoprost and Timolol in Glaucoma and Ocular HypertensionArchives of Ophthalmology (1950), 2002
- The Pharmacology of Bimatoprost (Lumigan™)Survey of Ophthalmology, 2001